EA201792651A1 - Аденовирусные полинуклеотиды и полипептиды - Google Patents

Аденовирусные полинуклеотиды и полипептиды

Info

Publication number
EA201792651A1
EA201792651A1 EA201792651A EA201792651A EA201792651A1 EA 201792651 A1 EA201792651 A1 EA 201792651A1 EA 201792651 A EA201792651 A EA 201792651A EA 201792651 A EA201792651 A EA 201792651A EA 201792651 A1 EA201792651 A1 EA 201792651A1
Authority
EA
Eurasian Patent Office
Prior art keywords
amino acid
acid sequence
polypeptides
seq
polypeptide
Prior art date
Application number
EA201792651A
Other languages
English (en)
Other versions
EA038402B9 (ru
EA038402B1 (ru
Inventor
Вирджиниа Аммендола
Стефано Коллока
Риккардо Кортезе
Фабьяна Грациоли
Альфредо Никозиа
Алессандра Вителли
Original Assignee
Глаксосмитклайн Байолоджикалс Са
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2015/063248 external-priority patent/WO2015189425A1/en
Priority claimed from GBGB1510357.5A external-priority patent/GB201510357D0/en
Priority claimed from GBGB1514772.1A external-priority patent/GB201514772D0/en
Application filed by Глаксосмитклайн Байолоджикалс Са filed Critical Глаксосмитклайн Байолоджикалс Са
Publication of EA201792651A1 publication Critical patent/EA201792651A1/ru
Publication of EA038402B1 publication Critical patent/EA038402B1/ru
Publication of EA038402B9 publication Critical patent/EA038402B9/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/075—Adenoviridae
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/75—Fibrinogen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10371—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Abstract

Предложен, в частности, выделенный полинуклеотид, который кодирует полипептид, выбранный из группы, состоящей из: (а) полипептида, имеющего аминокислотную последовательность SEQ ID NO: 1, (б) функционального производного полипептида, имеющего аминокислотную последовательность SEQ ID NO: 1, где функциональное производное имеет аминокислотную последовательность, которая по меньшей мере на 80% идентична на всем своем протяжении аминокислотной последовательности SEQ ID NO: 1, и (в) полипептида, имеющего аминокислотную последовательность SEQ ID NO:3.
EA201792651A 2015-06-12 2016-06-10 Аденовирусные полинуклеотиды и полипептиды EA038402B9 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
PCT/EP2015/063248 WO2015189425A1 (en) 2014-06-13 2015-06-12 Immunogenic combinations
GBGB1510357.5A GB201510357D0 (en) 2015-06-12 2015-06-12 Adenovirus polynucleotides and polypeptides
GBGB1514772.1A GB201514772D0 (en) 2015-08-19 2015-08-19 Adenovirus polynucleotides and polypeptides
PCT/EP2016/063329 WO2016198621A1 (en) 2015-06-12 2016-06-10 Adenovirus polynucleotides and polypeptides

Publications (3)

Publication Number Publication Date
EA201792651A1 true EA201792651A1 (ru) 2018-06-29
EA038402B1 EA038402B1 (ru) 2021-08-23
EA038402B9 EA038402B9 (ru) 2021-09-22

Family

ID=57503533

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201792651A EA038402B9 (ru) 2015-06-12 2016-06-10 Аденовирусные полинуклеотиды и полипептиды

Country Status (13)

Country Link
US (4) US11254711B2 (ru)
EP (2) EP3307313A1 (ru)
JP (2) JP6983665B2 (ru)
KR (2) KR102535670B1 (ru)
CN (2) CN108025058B (ru)
AU (4) AU2016275619B2 (ru)
BE (1) BE1024420B1 (ru)
BR (1) BR112017026523A2 (ru)
CA (2) CA2988654A1 (ru)
EA (1) EA038402B9 (ru)
IL (2) IL256069B2 (ru)
MX (2) MX2017016101A (ru)
WO (2) WO2016198599A1 (ru)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3307313A1 (en) 2015-06-12 2018-04-18 GlaxoSmithKline Biologicals SA Adenovirus polynucleotides and polypeptides
GB201513176D0 (en) 2015-07-27 2015-09-09 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response
MX2019006722A (es) * 2016-12-09 2019-08-22 Glaxosmithkline Biologicals Sa Construcciones de adenovirus de chimpance con antigenos de lyssavirus.
GB201620968D0 (en) 2016-12-09 2017-01-25 Glaxosmithkline Biologicals Sa Adenovirus polynucleotides and polypeptides
WO2019016756A1 (en) 2017-07-21 2019-01-24 Glaxosmithkline Biologicals Sa ANTIGEN CONSTRUCTS OF CHIKUNGUNYA VIRUSES
WO2019076882A1 (en) 2017-10-16 2019-04-25 Glaxosmithkline Biologicals Sa ADENOVIRAL VECTORS COMPRISING TWO EXPRESSION CASSETTES ENCODING RSV ANTIGENIC PROTEINS OR FRAGMENTS THEREOF
AR113450A1 (es) 2017-10-16 2020-05-06 Glaxosmithkline Biologicals Sa Vectores adenovirales competentes en la replicación
WO2019076892A1 (en) 2017-10-16 2019-04-25 Glaxosmithkline Biologicals Sa ENHANCED PROMOTER
MX2020003746A (es) 2017-10-16 2020-11-06 Glaxosmithkline Biologicals Sa Vectores adenovirales con dos casetes de expresion.
CN111295391B (zh) * 2017-10-31 2023-12-05 扬森疫苗与预防公司 腺病毒及其用途
GB201721068D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B immunisation regimen and compositions
GB201721069D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B Immunisation regimen and compositions
BR112020012361A2 (pt) * 2017-12-20 2020-11-24 Glaxosmithkline Biologicals S.A. constructos de antígeno do vírus epstein-barr
CN112638936A (zh) * 2018-06-12 2021-04-09 葛兰素史密丝克莱恩生物有限公司 腺病毒多核苷酸和多肽
EA202190114A1 (ru) * 2018-06-25 2021-05-12 Акуос, Инк. Способы лечения clrn1-ассоциированной потери слуха и/или потери зрения
EP3587581A1 (en) 2018-06-26 2020-01-01 GlaxoSmithKline Biologicals S.A. Formulations for simian adenoviral vectors having enhanced storage stability
EP3810277A1 (en) * 2018-07-20 2021-04-28 Janssen Vaccines & Prevention B.V. Recombinant adenoviral vector expressing zika antigen with improved productivity
CN112601545A (zh) 2018-08-07 2021-04-02 葛兰素史密丝克莱恩生物有限公司 工艺和疫苗
WO2020128012A1 (en) 2018-12-21 2020-06-25 Glaxosmithkline Biologicals Sa Methods of inducing an immune response
CA3132601A1 (en) 2019-03-05 2020-09-10 Glaxosmithkline Biologicals Sa Hepatitis b immunisation regimen and compositions
US20230109362A1 (en) 2020-05-14 2023-04-06 Glaxosmithkline Biologicals Sa Viral biosensors

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8919102D0 (en) * 1989-08-22 1989-10-04 Oxford Virology Ltd A recombinant adenovirus dna sequence,a recombinant adenovirus expressing the dna sequence and a rhabdovirus vaccine including the recombinant adenovirus
EP1409012B1 (en) 2001-06-22 2009-02-11 The Wistar Institute Of Anatomy And Biology Methods of inducing a cytotoxic immune response and recombinant simian adenovirus compositions useful therein
CA2466431C (en) * 2001-11-21 2014-08-05 The Trustees Of The University Of Pennsylvania Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use
US7030094B2 (en) 2002-02-04 2006-04-18 Corixa Corporation Immunostimulant compositions comprising an aminoalkyl glucosaminide phosphate and QS-21
US7960522B2 (en) 2003-01-06 2011-06-14 Corixa Corporation Certain aminoalkyl glucosaminide phosphate compounds and their use
US7205342B2 (en) * 2003-10-10 2007-04-17 General Electric Company Poly(arylene ether) composition and method of molding
LT2163260T (lt) * 2004-01-23 2017-06-26 Msd Italia S.R.L. Šimpanzės adenoviruso vakcinos nešikliai
WO2006078294A2 (en) 2004-05-21 2006-07-27 Novartis Vaccines And Diagnostics Inc. Alphavirus vectors for respiratory pathogen vaccines
NZ581306A (en) * 2004-11-16 2011-03-31 Crucell Holland Bv Multivalent vaccines comprising recombinant viral vectors
EP1880012B1 (en) * 2005-05-12 2015-07-08 Glaxo Group Limited Vaccine composition
EP1893636A2 (en) * 2005-06-17 2008-03-05 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Hepatitis c virus nucleic acid vaccine
MX362698B (es) 2007-03-02 2019-02-01 Glaxosmithkline Biologicals Sa Metodo novedoso y composiciones.
GB0706914D0 (en) * 2007-04-10 2007-05-16 Isis Innovation Novel adenovirus vectors
EP2463362B1 (en) 2007-11-28 2017-11-08 The Trustees Of The University Of Pennsylvania Simian subfamily c adenovirus SAdv-31 and uses thereof
PL2220241T3 (pl) * 2007-11-28 2017-06-30 The Trustees Of The University Of Pennsylvania Adenowirus zawierający kapsydowe białko heksonu SAdV-39 małpiego adenowirusa E oraz jego zastosowanie
KR101761683B1 (ko) * 2007-11-28 2017-07-26 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 유인원 아과 ｂ 아데노바이러스 ｓａｄｖ-28,27,-29,-32,-33, 및 -35 및 그것의 사용
EP2250255A2 (en) * 2008-03-04 2010-11-17 The Trustees of the University of Pennsylvania Simian adenoviruses sadv-36,-42.1, -42.2, and -44 and uses thereof
CA2726914A1 (en) 2008-06-03 2009-12-10 Okairos Ag A vaccine for the prevention and therapy of hcv infections
WO2010085984A1 (en) * 2009-02-02 2010-08-05 Okairos Ag Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof
SG172935A1 (en) * 2009-02-02 2011-08-29 Okairos Ag Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof
CA2762203A1 (en) * 2009-05-29 2010-12-02 Soumitra Roy Simian adenovirus 41 and uses thereof
EP2459716B1 (en) * 2009-07-31 2016-08-17 Paxvax, Inc. Adenoviral-based vectors
US9526777B2 (en) * 2010-04-16 2016-12-27 The United States Of America As Represented By The Department Of Health And Human Services Methods for the induction of ebola virus-specific immune responses comprising administering a replication-defective chimpanzee adenovirus vector expressing the ebola virus glycoprotein
AU2011258156B2 (en) 2010-05-26 2016-11-24 Selecta Biosciences, Inc. Multivalent synthetic nanocarrier vaccines
GB201016471D0 (en) * 2010-09-30 2010-11-17 Isis Innovation Viral vector immunogenic compositions
US20120328605A1 (en) 2010-10-27 2012-12-27 Daniel Larocque Compositions and uses
WO2012089231A1 (en) 2010-12-30 2012-07-05 Okairòs Ag Paramyxovirus vaccines
GB201108879D0 (en) * 2011-05-25 2011-07-06 Isis Innovation Vector
EP2729168A2 (en) * 2011-07-06 2014-05-14 Novartis AG Immunogenic compositions and uses thereof
FR2978457A1 (fr) * 2011-07-27 2013-02-01 Univ Paris Diderot Paris 7 Composes contenant un vecteur viral a specificite hepatique et presentant une activite anti-inflammatoire
EP2764012B1 (en) 2011-10-05 2022-02-23 GenVec, Inc. Adenoviral vectors and methods of use
CN103239734B (zh) * 2012-02-10 2016-02-24 北京艾棣维欣生物技术有限公司 用于预防和/或治疗呼吸道合胞病毒感染的疫苗
MY169331A (en) 2012-03-22 2019-03-21 Janssen Vaccines & Prevention Bv Vaccine against rsv
JP6523955B2 (ja) 2012-08-01 2019-06-05 バヴァリアン・ノルディック・アクティーゼルスカブ 組換え改変ワクシニアウイルスアンカラ（ｍｖａ）ｒｓウイルス（ｒｓｖ）ワクチン
JP2016501196A (ja) 2012-11-20 2016-01-18 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Ｒｓｖｆ融合前三量体
DE102012221236A1 (de) 2012-11-21 2014-05-22 Zf Friedrichshafen Ag Getriebe
GB201303406D0 (en) * 2013-02-26 2013-04-10 Health Prot Agency Crimean-Congo Haemorrhagic Fever Virus Antigenic Composition
AU2014253791B2 (en) 2013-04-18 2019-05-02 Immune Design Corp. GLA monotherapy for use in cancer treatment
CN103937835A (zh) * 2013-08-19 2014-07-23 中国科学院上海巴斯德研究所 一种基于腺病毒AdC68的表达载体及其构建方法
CN103923943B (zh) * 2013-08-19 2019-01-22 中国科学院上海巴斯德研究所 一种基于腺病毒AdC7的表达载体及其构建方法
GB201318084D0 (en) * 2013-10-11 2013-11-27 Isis Innovation Malaria vaccination
EP3154576A1 (en) 2014-06-13 2017-04-19 GlaxoSmithKline Biologicals S.A. Immunogenic combinations
EP3307313A1 (en) 2015-06-12 2018-04-18 GlaxoSmithKline Biologicals SA Adenovirus polynucleotides and polypeptides

Also Published As

Publication number Publication date
AU2016275601A1 (en) 2018-01-18
WO2016198599A1 (en) 2016-12-15
IL256069B2 (en) 2023-07-01
JP2018524977A (ja) 2018-09-06
US11254710B2 (en) 2022-02-22
JP6873054B2 (ja) 2021-05-19
IL256121B2 (en) 2023-02-01
BE1024420B1 (fr) 2018-02-19
EA038402B9 (ru) 2021-09-22
AU2019202081B2 (en) 2021-09-23
IL256069B1 (en) 2023-03-01
BE1024420A1 (fr) 2018-02-12
JP2018523980A (ja) 2018-08-30
AU2016275619A1 (en) 2018-01-04
AU2019271972A1 (en) 2019-12-19
US20220220157A1 (en) 2022-07-14
EP3307314A1 (en) 2018-04-18
AU2016275619B2 (en) 2019-09-19
CA2988481A1 (en) 2016-12-15
JP6983665B2 (ja) 2021-12-17
US11254711B2 (en) 2022-02-22
CN107921118A (zh) 2018-04-17
IL256121B (en) 2022-10-01
EP3307313A1 (en) 2018-04-18
BR112017026523A2 (pt) 2018-08-14
US20220204566A1 (en) 2022-06-30
KR20180011265A (ko) 2018-01-31
KR20180012857A (ko) 2018-02-06
CA2988654A1 (en) 2016-12-15
MX2017016101A (es) 2018-02-21
MX2017016105A (es) 2018-05-15
CN108025058B (zh) 2022-12-16
CN107921118B (zh) 2022-11-08
CN108025058A (zh) 2018-05-11
IL256069A (en) 2018-01-31
EA038402B1 (ru) 2021-08-23
KR102535670B1 (ko) 2023-05-22
AU2019202081A1 (en) 2019-04-18
US20200140886A1 (en) 2020-05-07
WO2016198621A1 (en) 2016-12-15
AU2019271972B2 (en) 2022-03-31
US20180170972A1 (en) 2018-06-21
IL256121A (en) 2018-02-28

Similar Documents

Publication Publication Date Title
EA201792651A1 (ru) Аденовирусные полинуклеотиды и полипептиды
EA201791426A1 (ru) Полипептид и иммуномодуляция
EA201890640A1 (ru) Рекомбинантные векторы, содержащие пептид 2а
TN2017000085A1 (en) Polypeptide having a polyester degrading activity and uses thereof
UA124343C2 (uk) Капсиди аденоасоційованого вірусу і спосіб його використання
EA201991116A1 (ru) Полинуклеотиды и полипептиды аденовируса
PE20161442A1 (es) Proteinas quimericas tipo fosfatasa alcalina
MX2017009595A (es) Compuestos antisenescentes y usos de los mismos.
HRP20210734T1 (hr) Koštani morfogenetski proteini
PE20170955A1 (es) Nuevas proteinas inhibidoras de insectos
EP4059961A3 (en) Anti-tau constructs
UY36565A (es) Variantes de polipéptidos que dividen toxinas de fusarium, aditivo que contiene estas variantes y su uso, asi como procedimientos para la division de toxinas de fusarium
PH12017502323A1 (en) Novel xylanase
EA201792362A8 (ru) Композиции и способы для лечения целиакии спру
WO2015185758A3 (en) Preparation comprising factor viii and von willebrand factor peptides
EA201591609A1 (ru) Варианты альфа-амилазы
CL2017000200A1 (es) Célula huésped mejorada para producir proteinas
MX2020013553A (es) Polinucleotidos y polipeptidos de adenovirus.
WO2015107363A3 (en) Mycobacterial antigen composition
AR101146A1 (es) Proteína con actividad xilanasa
EA201692439A1 (ru) Пролин-специфичная эндопротеаза и ее применение
PH12017550134A1 (en) Il-37 variants
MX2021003441A (es) Polipeptidos de arginasa1.
EA201792648A1 (ru) Аденовирусные полинуклеотиды и полипептиды
EA202092963A1 (ru) Новый белок с противовоспалительными свойствами

Legal Events

Date Code Title Description
TH4A Publication of the corrected specification to eurasian patent